AGIOS PHARMACEUTICALS, INC. Cash and Cash Equivalents, Fair Value Disclosure
AGIOS PHARMACEUTICALS, INC. (AGIO) had Cash and Cash Equivalents, Fair Value Disclosure of $38.74 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-07-30
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $38.74M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $74.00M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $50.84M.
- 2017-03-31: Cash and Cash Equivalents, Fair Value Disclosure $198.65M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $38.74M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $74.00M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $50.84M 10-K · filed 2026-02-12 |
| 2017-03-31 | $198.65M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $151.25M 10-K · filed 2017-02-16 |
| 2016-09-30 | $276.77M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $225.56M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $26.84M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $59.33M 10-K · filed 2017-02-16 |
| 2014-12-31 | $12.37M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |